Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

NCT02273960 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenic Purpura

Interventions

DRUG: BMS-986004 75 mg IV
DRUG: BMS-986004 225 mg IV
DRUG: BMS-986004 675 mg IV
DRUG: BMS-986004 1500 mg IV

Sponsor

Bristol-Myers Squibb